Onco Wiki / Maladie

Carcinome thyroïdien papillaire (CPT)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-THYROID-PAPILLARY
TypeMaladie
Alias
PTCCarcinome thyroïdien papillaireПапілярна карцинома щитовидної залози
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-CNS-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8260/3
icd_o_3_topography["C73"]
icd_10C73
who_classificationWHO Endocrine Tumours 5th ed (2022): Papillary thyroid carcinoma (follicular cell origin)

Capacités

Notes

Differentiated thyroid carcinoma — most indolent of common cancers. Standard care: surgery → risk-stratified RAI ablation → TSH suppression → calibrated thyroglobulin (Tg) monitoring. Radioiodine-refractory progressive disease is the trigger for systemic therapy: - Multikinase TKI 1L: lenvatinib (SELECT) or sorafenib (DECISION). - Targeted by genotype: * BRAF V600E (~50% PTC): dabrafenib + trametinib (MARCH/REINK compassionate-use; FDA tumor-agnostic 2022 BRAF V600E approval for solid tumors); single-agent dabrafenib also active. * RET fusion: selpercatinib (LIBRETTO-531; positive 2024) and pralsetinib (ARROW) — selpercatinib FDA-approved for RET-fusion+ thyroid cancer. * NTRK fusion: larotrectinib / entrectinib (tumor-agnostic). * Re-differentiation strategies: short-course MAPK inhibitor (selumetinib / dabrafenib + trametinib) restoring RAI uptake — under study. Aggressive variants (tall cell, hobnail, columnar, diffuse sclerosing) upstage to higher recurrence-risk groups even when small.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte